Background: Knowledge on the molecular epidemiology of Escherichia coli causing E. coli 27 bacteremia (ECB) in the Netherlands is almost exclusively based on extended-spectrum beta-28 lactamase producing E. coli isolates (ESBL-PEc) that are responsible for about 10% of all ECB 29 episodes. We determined clonal differences and differences in resistance and virulence gene 30 content between non-ESBL-producing E. coli (non-ESBL-PEc) and ESBL-PEc isolates with 31 different epidemiological characteristics. 32
INTRODUCTION
content and serotype distribution between isolates with different clinical epidemiological 76 characteristics and between non-ESBL-producing E. coli (non-ESBL-PEc) and ESBL-producing 77 E. coli (ESBL-PEc) blood isolates. 78
METHODS 79

Study design 80
Details of the study design, epidemiological data collection and laboratory methods (i.e. 81 phenotypic ESBL detection) are described elsewhere [12] . In short, patients with ECB were 82 retrospectively identified from medical microbiological records in the University Medical Center 83 Utrecht (UMCU), a 1,042-bed tertiary care center and the Amphia Hospital in Breda, an 837-bed 84 teaching hospital. In each hospital, we selected a random sample of 40 isolates of unique 85
patients per year for the years 2014, 2015 and 2016, comprising ~24% of all first bacteremic E. 86 coli isolates in a year. In addition to this random sample, all ESBL-PEc blood isolates from 2014 87 -2016 were selected from the two hospitals. Whole genome sequencing (WGS) was performed 88 by The Netherlands National Institute for Public Health and the Environment (RIVM) using the 89 Illumina HiSeq 2500 (BaseClear, Leiden, the Netherlands). De novo assembly was performed 90 using SPAdes genome assembler v.3.6.2 and the quality of assembles was assessed using 91 QUAST [13] . Only genomes with an estimated genome size between 3 MB and 6 MB and 92 number of contigs not exceeding 1,000 were included in further analyses. Baseline clinical 93 epidemiological characteristics were compared between the non-ESBL-PEc and ESBL-PEc 94 ECB episodes. ESBL-production was defined as confirmed phenotypic ESBL-positivity, unless 95 described otherwise [12] . Baseline characteristics were compared by the Fisher's Exact or 96 need for official approval by the Ethics Committee (IRB number 18/056) and informed consent 101 was not obtained. All statistical analyses were performed with Statistical Package for Social 102 Sciences V.25.0 (SPSS, Chicago, Illinois, USA) and R Version 3.4.1. Boxplots were made with 103 R packages ggplot2 and ggpubr and bar charts were made with Graphpad Prism Version 8.0.1. 104
Multi-locus sequence types (MLST) 105
Multi-locus sequence types (STs) were determined using mlst2.0 106 (https://github.com/tseemann/mlst) by scanning contig files against the E. coli PubMLST typing 107 scheme (updated May 12th, 2018) . ST (i.e. clonal) distribution was presented stratified for non-108
ESBL-PEc and ESBL-PEc isolates and by epidemiological subgroup (i.e. community versus 109 hospital onset; different primary foci of ECB). Genotype (ST) diversity was analysed by 110
Simpson's diversity index [14] . A core-genome (cg) neighbour-joining (NJ) phylogenetic tree 111 was constructed in Seqsphere with the Escherichia/Shigella cgMLST v1 scheme developed by 112 Enterobase (https://enterobase.warwick.ac.uk/species/index/ecoli), containing 2,513 target 113 genes and visualised using the free online available web-tool Microreact 114 (https://microreact.org/showcase) [15] . The cgNJ method reconstructs phylogeny by using a 115 distance matrix that contains the genetic distance between each pair of sequences. 116
Serotyping 117
We assigned serotypes by using the web-tool SerotypeFinder 2.0 from the Center for Genomic 118 [18, 19] . 129
The thresholds for coverage length and sequence identity were 80% and 95%, respectively. A 130 resistance gene count using each of the databases was made per isolate, which was defined as 131 the total number of resistance genes (using CARD) and the total number of acquired resistance 132 genes (using ResFinder) identified, respectively. In case of double detection of identical 133
resistance genes within a single isolate, they were only counted once. The resistance gene 134 scores were compared between non-ESBL-PEc and ESBL-PEc with the non-parametric 135
Wilcoxon rank sum test (for this comparison only, the scores of the ESBL-PEc isolates were 136 corrected for presence of the ESBL gene). Resistance gene scores were then analysed for non-137 ESBL-PEc and ESBL-PEc separately and were compared between isolates with different 138 epidemiological characteristics and different STs using Kruskal-Wallis one-way ANOVA. In case 139 of an overall ANOVA P value <0.05, post-hoc pairwise comparisons were made and the Holm-140
Bonferroni P value correction was applied to account for multiple testing. For pairwise 141 comparisons, the non-parametric Wilcoxon rank sum test was used. 142
Virulence genes 143
The presence of putative virulence factor genes (VG) was identified using abricate version 144 0.8.13 for BLAST against the VFDB database (http://www.mgc.ac.cn/VFs), date of download 8 145
February 2019, with minimal coverage length and sequence identity 80% and 95% [20] . We 146 searched for 49 putative VG that were previously described as extra-intestinal pathogenic E. coli BLAST against the ecoli_VF_collection database was performed (date 8 February 2019), a 149 repository that contains known VG from VFDB supplemented with additional E. coli VG that 150 have been reported in literature [26] . The kpsM, afa/dra and sfa/foc operons were considered 151 present if any of the corresponding genes or allelic variants were identified. A virulence score 152 was made per isolate and was defined as the total number of pre specified VG, adjusted for 153 multiple detection of the afa/dra (Afa/Dr adhesins), pap (P fimbrial adhesins), sfa/foc (S and F1C 154 fimbrial adhesins) and kpsM (group 2 and III capsule) operons, as described previously [23] . If a 155 VG was detected multiple times within a single isolate (i.e. with different quality measures), it 156 was only counted once. These virulence scores were then compared between isolates with 157 different epidemiological characteristics and between different STs using Kruskal-Wallis one-158 way ANOVA. In case of an overall ANOVA P value <0.05, post-hoc pairwise comparisons were 159 made with the non-parametric Wilcoxon rank sum test and the Holm-Bonferroni P value 160 correction was applied to account for multiple testing. 161
RESULTS 162
Patient characteristics 163
The isolate collection consisted of 212 phenotypic non-ESBL-PEc and 69 ESBL-PEc blood 164 isolates ( Fig. 1 ). Distribution of age, sex, onset of infection and primary foci were comparable 165 between non-ESBL-PEc and ESBL-PEc bacteremia episodes (Table 1) . As compared to non-166 ESBL-PEc, ECB episodes with ESBL-PEc were less often of community onset (63.8% versus 167 81.1%, P value = 0.003). Crude 30-day and 1-year mortality was higher in ECB episodes 168 caused by ESBL-PEc (27.5% and 50.7%, respectively) in comparison with ECB episodes 169 caused by non-ESBL-PEc (11.3% and 29.2%, respectively). 170 higher than among non-ESBL-PEc (P value < 0.001). Simpson's index for ST diversity was 176 95.6% (95% CI 94.4% -96.8%) and 80.6% (95% CI 70.9% -90.4%) for non-ESBL-PEc and 177 ESBL-PEc, respectively. The occurrence of different STs did not differ between nosocomial and 178 community onset ECB (S1 Figure and S2 Table) . ST131 was the dominant ST among ESBL-179 positive ECB episodes with a primary urinary (63%) and hepatic-biliary focus (57%), which was 180 higher as compared to other primary foci of ESBL-positive ECB (i.e. 21% among primary 181 hepatic-biliary focus, see S3 Figure and S4 Table) . The NJ-phylogenetic tree of all isolates can 182 be found in the Supporting Information (S5 Figure) . The most common serotype was O25:H4 and was identified in 19 (9.0%) non-ESBL-PEc and 24 195 (34.8%) ESBL-PEc isolates, which largely reflected the prevalence of ST131 in each group 196 ( Table) . 
Antimicrobial resistance genes 208
In total, 110 unique resistance genes were identified with CARD and 69 unique acquired 209 resistance genes were identified with ResFinder 3.1.0 (see S7 Table) . ESBL-genes were 210 detected in 65 (94.2%) of 69 E. coli blood isolates with phenotypic ESBL production. bla CTX-M-15 211 was the most prevalent ESBL gene (N = 28, 43.1%), followed by bla CTX-M-9 (N = 14, 21.5%) and 212 bla CTX-M-27 (N = 9, 13.8%). Assemblies of the phenotypic ESBL-PEc isolates in which no ESBL-213 gene was identified (N = 4) were individually uploaded on the DTU Resfinder 3.1.0 website 214 (date 11 March 2019, thresholds for coverage length 80% and sequence identity 95%); these 215 (IQR 43 -50) for ESBL-PEc iolates (P value < 0.001). The median acquired resistance gene 219 count for non-ESBL-PEc versus ESBL-PEc was 1 (IQR 1 -6) versus 7 (IQR 4 -9) (P value < 220 0.001). Among non-ESBL-PEc, total and acquired resistance gene counts were not different 221 between community and hospital-onset ECB episodes (S8 Figure and S9 Table) . Among non-222 ESBL-PEc, there were statistically significant differences in resistance gene count for different 223 primary foci of ECB, but absolute differences were small (S8 Figure) . The median acquired 224 resistance gene count of non-ESBL-PEc isolates from ECB with a primary hepatic-biliary focus 225 was 1 (IQR 1 -1), whereas for a primary urinary focus this was 2 (IQR 1 -6) (P value ≤0.001), 226 primary gastro-intestinal focus this was 4 (IQR 1 -8) (P value ≤0.01) and unknown primary 227 focus this was 1 (IQR 1 -6) (P value ≤0.0001) (S9 Table) . Among ESBL-PEc isolates, there 228
were no statistical significant differences in total and acquired resistance gene counts between 229 community and hospital-onset ECB or different primary foci of ECB (S8 Figure and S9 Table) . 230
Among non-ESBL-PEc, there was heterogeneity in total resistance gene count between almost 231 all dominant STs; this was not the case for acquired resistance gene count ( Fig. 3 and S10 232 Table) . No statistically significant differences were observed among ESBL-PEc isolates of 233 different STs (S10 Table) . N = 212 (%) 
ESBL-PEc
243
that occurred >5% within ESBLs or non-ESBLs were grouped into main groups, the rest was categorized as "Other".
244
Results of the pairwise comparisons can be found in S10 Table. 245 246
Virulence genes 247
Of the 49 predefined ExPEC-associated VG, 44 (89.8%) were detected in at least one E. coli 248 blood isolate (S11 Table) . The median VG score was 13 (IQR 9 -20) for non-ESBL-PEc and 12 249 (IQR 8 -14) for ESBL-PEc blood isolates (P value = 0.002). In one non-ESBL-PEc isolate no 250 predefined ExPEC-associated VG was detected, while a maximum VG score of 25 was found in 251 two non-ESBL-PEc isolates. 252
For non-ESBL-PEc and ESBL-PEc isolates, there was no significant difference in the VG 253 score between isolates that caused community or hospital onset ECB (S13 Table) . Non-ESBL-254
PEc isolates that caused ECB with a primary gastro-intestinal focus (median 10, IQR 6 -13) 255
and hepatic-biliary focus (median 11, IQR 5 -18) had lower VG scores as compared to isolates 256 with a primary focus in the urinary tract (median 15, IQR 11 -21) (P value = 0.007 and P value 257 = 0.036, respectively, see S12 Figure and S13 Table) . Among non-ESBL-PEc and ESBL-PEc, 258 there were no statistical significant differences in VG scores between isolates of patients without versus with a urinary catheter, between patients alive or deceased after 30 days or between 260 patients admitted to the intensive care unit (ICU) versus a non-ICU ward (data not shown). 261
There was heterogeneity in VG scores between non-ESBL-PEc of different STs, this 262 was less pronounced for ESBL-PEc isolates (Fig. 4 and S14 Table) . ESBL-negative ST38 had 263 the lowest average VG score (median 7, IQR 6 -7) and ESBL-positive ST12 had the highest 264 VG score (median 23, IQR 23 -23). Median VG score of both ESBL-negative and ESBL-265 positive ST131 isolates was 13 . All pairwise comparisons between ESBL-266 negative STs yielded Holm-Bonferroni adjusted P values < 0.05, except for the comparison 267 ST12 versus ST73 and all pairwise comparisons that included ST38. 268 
272
Boxplots display median VG score and inter quartile range (IQR); and every dot represents a single isolate. Only STs 273 that occurred >5% within ESBLs or non-ESBLs were grouped into main groups, the rest was categorized as "Other".
274
Results of pairwise comparisons can be found in S14 Table. 275 276
DISCUSSION 277
In this study, we found that ESBL-producing E. coli blood isolates were different from non-278 has been described before [29, 30] . In contrast, ST73, a ST that is known for its susceptible 283 antibiotic profile [29] , was only identified among non-ESBL-PEc blood isolates. The association 284 between ESBL phenotype and STs in E. coli, which is repeatedly found, implies that the 285 molecular backbone of strains can increase (or decrease) its propensity to acquire and 286 subsequently maintain plasmids carrying ESBL genes. A recent large-scale study that 287 compared the pan-genomes of invasive E. coli isolates, including ST131 and ST73, suggested 288 that due to ongoing adaptation to long term human intestinal colonisation and consequent 289 evolutionary gene selection, ST131 might have become able to reduce the fitness costs of long 290 term plasmid maintenance [31, 32] . Interestingly, in our study, isolates that belonged to ST73 291 had low resistance gene content but relatively high VG score as compared to other STs. 292
Furthermore, the average VG score among non-ESBL-PEc was slightly higher in comparison to 293 ESBL-PEc blood isolates, which demonstrates that ESBL-positivity in E. coli is not necessarily 294 related to an increased VG content. In case we would assume that VG content is associated 295 with virulent potential, i.e. the ability of a strain to cause invasive disease, then these findings do 296 not support the theory that increased virulence of resistant strains causes the increased 297 incidence of resistant ECB as compared to sensitive ECB. This theory has been suggested for 298 other pathogens, such as MRSA [1, 33, 34] . Still, results of the current study show that molecular 299 characteristics of ESBL-PEc cannot be merely generalized to non-ESBL-PEc blood isolates, 300 highlighting the importance of not preselecting on ESBL-positivity when investigating the 301 molecular epidemiology of ECB. 302
One of our hypotheses was that the distributions of STs, resistance gene and VG 303 content would differ between ECB episodes of community and hospital onset and between 304 different primary foci, as a possible result of different levels of sub specialization of intestinal E. subgroups, but found that these differences in molecular content mostly depended on performed in Scotland [35] . In that study, there were combinations of virulence genes as well as 309 a particular accessory gene composition that differentiated between STs rather than between 310 epidemiological factors. The association between ST69 and community onset ECB, as found in 311 the Scottish study, was not identified in the current study. Other differences were the large 312
proportion of E. coli isolates from ECB episodes that were deemed hospital-acquired (62%) as 313 compared to our study (18.4% for ESBL-negative and 36.2% for ESBL-positive ECB) and in that 314 study, analyses were not stratified for ESBL-positivity. More studies that combine clinical 315 characteristics with molecular characteristics of ECB are important, because these data help to 316 further elucidate the role of host-specific factors versus strain-specific factors in the 317 pathogenesis of ECB. Since different determinants of ECB might indicate different targets for 318 surveillance or infection-prevention, a thorough understanding of the molecular epidemiology is 319 needed to reduce the occurrence of this invasive infectious disease with potential severe clinical 320
consequences. 321
We identified serotype O25:H4 as the most prevalent serotype causing ESBL-negative 322 as well as ESBL-positive ECB in the Netherlands, followed by O6:H1. The serotype distribution 323 among non-ESBL-PEc was more heterogeneous as compared to ESBL-PEc, similar to the 324 differences in clonal diversity between these two groups. A large recent European surveillance 325 study that included 1,110 E. coli blood isolates from adults between 2011 and 2017 showed that 326 there is heterogeneity in serotype distribution among different countries, which highlights the 327 need for country specific data [17] . Furthermore, we showed that the coverage of the new 328 potential 10-valent vaccine was higher as compared to the 4-valent vaccine and was actually 329 doubled for non-ESBL-PEc bacteremia. The findings of the current study can be used for future 330 studies and can help further evaluation and implementation of E. coli vaccines. epidemiological characteristics and highly discriminatory genetic data. There are also important 333 limitations. Firstly, E. coli is a heterogeneous species, of which the seven MLST genes only 334 constitute a small proportion of the entire gene content. Because we also only investigated 335 presence of a small fraction of the genes that are commonly part of the accessory genome, 336 such as virulence and acquired resistance genes, but did not assess the entire accessory gene 337 pool, we could have missed genomic differences between isolates that are reflected in the 338 accessory gene pool only. Secondly, we selected E. coli isolates from a tertiary care center and 339 teaching hospital from the Netherlands from two different regions, which we considered to be 340
representative of the Netherlands. The description of strains that were identified here might not 341 be entirely generalizable to other countries since there could be differences between circulating 342 E. coli strains, dependent on local population characteristics and antimicrobial resistance levels. 343
Thirdly, many pairwise comparisons between subgroups were performed, which increases the 344 risk of false-positive findings (i.e. type I errors). Even though we applied a strict p-value 345 correction for multiple testing, this naturally does not eliminate the risk of false-positive findings. 346
The analyses on resistance gene and VG content should therefore be viewed as hypothesis 347 generating. 348
In conclusion, there are molecular differences between non-ESBL-PEc and ESBL-PEc 349 blood isolates that reach beyond their phenotypic ESBL positivity. Future genomic research of 350 E. coli should preferably focus on E. coli without preselection on ESBL-positivity, to limit the risk 351 of inferring characteristics of resistant E. coli to the E. coli population as a whole. Furthermore, 352 more studies are needed to better understand repeatedly found associations between gene 353 content and STs, which could aid the development of targeted preventive interventions. 354
